News and Announcements
Actinogen Receives US FDA Feedback to Enhance Alzheimers Study
- Published June 08, 2016 11:31AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
8th June 2016, ASX Announcement
Highlights:
- Productive interaction with the US Food and Drug Administration (FDA)
- Protocol enhancement will strengthen the value of the Phase II trial
- Harmonising Australian and UK trial with US FDA increases potential global value
- Fits into broader US strategy of medical publications slated for 2H16 and US investor campaign in 2H16
Actinogen Medical Limited (Actinogen Medical, ASX: ACW) is pleased to announce productive progress with the US Food and Drug Administration (FDA) to enhance the safety profile of XanADu, the Phrase II trial of its lead Alzheimer’s drug candidate, Xanamem™.
Good progress has been made with the Actinogen Medical team towards securing final US FDA approval under an Investigational New Drug (IND) for the Phase II study.
To view the full announcement, please click on the button below.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
